NO20004250D0 - Humaniserte anti-TAG-72 monoklonale antistoffer med høy affinitet - Google Patents
Humaniserte anti-TAG-72 monoklonale antistoffer med høy affinitetInfo
- Publication number
- NO20004250D0 NO20004250D0 NO20004250A NO20004250A NO20004250D0 NO 20004250 D0 NO20004250 D0 NO 20004250D0 NO 20004250 A NO20004250 A NO 20004250A NO 20004250 A NO20004250 A NO 20004250A NO 20004250 D0 NO20004250 D0 NO 20004250D0
- Authority
- NO
- Norway
- Prior art keywords
- tag
- monoclonal antibodies
- high affinity
- humanized anti
- affinity monoclonal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57469—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumor associated glycolinkage, i.e. TAG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1998/003679 WO1999043816A1 (en) | 1998-02-25 | 1998-02-25 | High affinity humanized anti-tag-72 monoclonal antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20004250D0 true NO20004250D0 (no) | 2000-08-24 |
NO20004250L NO20004250L (no) | 2000-10-24 |
Family
ID=22266462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20004250A NO20004250L (no) | 1998-02-25 | 2000-08-24 | Humaniserte anti-TAG-72 monoklonale antistoffer med høy affinitet |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1056860B1 (no) |
JP (1) | JP4080692B2 (no) |
AT (1) | ATE288960T1 (no) |
AU (1) | AU758358B2 (no) |
CA (1) | CA2321932A1 (no) |
DE (1) | DE69829001T2 (no) |
IL (1) | IL138021A0 (no) |
NO (1) | NO20004250L (no) |
WO (1) | WO1999043816A1 (no) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000026394A1 (en) * | 1998-10-31 | 2000-05-11 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Variants of humanized anti-carcinoma monoclonal antibody cc49 |
US6818749B1 (en) | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
US7319139B2 (en) | 2001-01-29 | 2008-01-15 | Biogen Idec, Inc. | TAG-72 specific CH2 domain deleted antibodies |
CA2490659C (en) | 2002-06-28 | 2014-08-19 | Syed V. S. Kashmiri | Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors |
US7589181B2 (en) | 2003-08-29 | 2009-09-15 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use |
KR100620554B1 (ko) * | 2004-06-05 | 2006-09-06 | 한국생명공학연구원 | Tag-72에 대한 인간화 항체 |
WO2006116076A2 (en) * | 2005-04-28 | 2006-11-02 | Genencor International, Inc. | Tab molecules |
KR20130114758A (ko) * | 2005-05-27 | 2013-10-17 | 오스페달레 산 라파엘 에스.알.엘. | Mi-rna를 포함하는 유전자 벡터 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR8907126A (pt) * | 1988-10-19 | 1991-02-13 | Dow Chemical Co | Uma nova familia de anticorpos modificados,de elevada afinidade,para tratamento de cancer |
-
1998
- 1998-02-25 CA CA002321932A patent/CA2321932A1/en not_active Abandoned
- 1998-02-25 EP EP98910057A patent/EP1056860B1/en not_active Expired - Lifetime
- 1998-02-25 AU AU64393/98A patent/AU758358B2/en not_active Ceased
- 1998-02-25 JP JP2000533556A patent/JP4080692B2/ja not_active Expired - Lifetime
- 1998-02-25 IL IL13802198A patent/IL138021A0/xx unknown
- 1998-02-25 AT AT98910057T patent/ATE288960T1/de not_active IP Right Cessation
- 1998-02-25 DE DE69829001T patent/DE69829001T2/de not_active Expired - Lifetime
- 1998-02-25 WO PCT/US1998/003679 patent/WO1999043816A1/en active IP Right Grant
-
2000
- 2000-08-24 NO NO20004250A patent/NO20004250L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO1999043816A1 (en) | 1999-09-02 |
AU758358B2 (en) | 2003-03-20 |
CA2321932A1 (en) | 1999-09-02 |
EP1056860B1 (en) | 2005-02-09 |
IL138021A0 (en) | 2001-10-31 |
DE69829001D1 (de) | 2005-03-17 |
JP2002504371A (ja) | 2002-02-12 |
ATE288960T1 (de) | 2005-02-15 |
JP4080692B2 (ja) | 2008-04-23 |
DE69829001T2 (de) | 2006-03-23 |
EP1056860A1 (en) | 2000-12-06 |
NO20004250L (no) | 2000-10-24 |
AU6439398A (en) | 1999-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1113326T1 (el) | Ανθρωπινα αντισωματα τα οποια δεσμευουν ανθρωπινη il-12 και μεθοδοι παραγωγης τους | |
IL165063A0 (en) | An antibody or fragment thereof that binds to human insulin-like growth factor-I receptor | |
EA200800094A1 (ru) | Антитела cd19 и их использование | |
HUP9901562A2 (hu) | Anti-CEA monoklonális antitestek, az ezeket tartalmazó konjugátumok és ezek felhasználása antitest irányított enzimes előgyógyszer terápiában | |
EA200800953A1 (ru) | Человеческие моноклональные антитела к cd70 | |
WO2005080431A3 (en) | Monoclonal antibodies that specifically bind to folate receptor alpha | |
SG170080A1 (en) | Human monoclonal antibodies to o8e | |
RS80704A (en) | ANTI- av?6.ANTIBODIES | |
AU2003205077A1 (en) | Imaging agents and methods of imaging naaladase of psma | |
WO2004009622A3 (en) | Protein complexes of cellular networks underlying the development of cancer and other diseases | |
HK1074634A1 (en) | Internalizing antibodies specific for the raag10 cell surface target | |
IN2009KN02404A (no) | ||
UA90082C2 (ru) | Выделенное моноклональное антитело человека, которое специфически связывается с cd25 человека и ингибирует связывание il-2 с cd25 | |
DE602006013029D1 (de) | Anti-egfr-antikörper | |
UA99701C2 (ru) | Человеческое моноклональное антитело, которое специфически связывается с лигандом-1 запрограммированной гибели клеток (pd-l1) | |
EP1708751A4 (en) | METHOD OF KILLING TUMOR CELLS BY TARGETING INTERNAL ANTIGEN EXPOSED ON APOPTOTIC TUMOR CELLS | |
SG146644A1 (en) | Kid3 and kid3 antibodies that bind thereto | |
EA200601405A1 (ru) | Гуманизированное антитело | |
WO2004060304A3 (en) | Novel compositions and methods in cancer | |
WO2004058146A3 (en) | Novel compositions and methods in cancer | |
WO2003064593A3 (en) | Antigen panels and methods of using the same | |
NO20004250L (no) | Humaniserte anti-TAG-72 monoklonale antistoffer med høy affinitet | |
ATE248189T1 (de) | Antikörper gegen vasp (vasodilator-stimulated phosphoprotein), hybridomzellen für deren gewinnung, und deren verwendung | |
NO20004251L (no) | Humaniserte anti-CEA monoklonale antistoffer med høy affinitet | |
WO2003080808A3 (en) | Novel compositions and methods in cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |